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Abstract
Background: In previous investigation, we reported that stably knocking down cyclin-dependent kinase 4(CDK4)
induced expression of let-7c, which further suppressed cell cycle transition and cell growth by modulating cell
cycle signaling in nasopharyngeal carcinoma (NPC). In this study, we further explored the molecular function
and mechanism of CDK4 modulating miRNAs to stimulate cell cycle transition, cell growth, and Cisplatin
(DDP) -resistance on in NPC.
Methods: We identified changes in miRNAs by miRNA array and real-time PCR and the effect on DDP after knocking
down CDK4 in NPC cells. Further, we investigated the molecular mechanisms by which CDK4 modulated miR-15a in NPC.
Moreover, we also explored the role of miR-15a and the effect on DDP in NPC. Finally, we analyzed the correlation of
miR-15a and CDK4 expression in NPC tissues.
Results: In addition to let-7 family members, we observed that upregulated expression of miR-15a was significantly
induced in CDK4-suppressed NPC cells. Further, we found that knocking down CDK4 suppressed c-Myc expression, and
the latter directly suppressed the expression of miR-15a in NPC. Furthermore, miR-15a as a tumor suppressor antagonized
CDK4 repressing cell cycle progression and cell growth in vitro and in vivo and induced the sensitivity of cells to DDP
by regulating the c-Myc/CCND1/CDK4/E2F1 pathway in NPC. Finally, miR-15a was negatively weak correlated with the
expression of CDK4 in NPC.
Conclusions: Our studies demonstrate that CDK4 and miR-15a comprise an abnormal automodulatory feedback loop
stimulating the pathogenesis and inducing chemotherapy resistance in NPC.
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Background
Cell cycle progression is controlled in part by a family of
cyclin proteins and cyclin dependent kinases (Cdks).
CDK4 is a member of cyclin-dependent kinase family,
and in complex with D-type cyclins, is thought to regu-
late cell growth during cell cycle transition from G1 to S
phase. In previous studies, CDK4 was reported to play a
significant role in promoting the pathogenesis of tumors
including oral squamous cell carcinoma [1], pancreatic
endocrine tumors [2], lung cancer [3, 4], nasopharyngeal
carcinoma [5–7], and other tumors [8–10].
MicroRNAs (miRNAs) are ~22-nucleotide (nt) small
RNAs that have emerged as important factors regulating
deadenylation, translation, and decay of their target
mRNAs. In recent years, many miRNAs were observed
to be deregulated and participate in the carcinogenesis
by modulating important tumor-associated genes [11–
15]. miR-93, derived from miR-106b-25 cluster, is ele-
vated in various types of cancers and plays oncogenic
roles by suppressing significant tumor suppressors in-
cluding PTEN, LATS2, and TGFBR2 et al. [16]. miR-18b
is a potential oncogene suppressed by CTGF through
PI3K/AKT/c-Jun/c-Myc to induce cell growth [17]. miR-
184 induced by PDCD4 directly suppressed c-Myc and
Bcl-2, which inhibited cell growth and stimulated cell
apoptosis in nasopharyngeal carcinoma [18].
NPC is one of the most common carcinomas with a
malignant phenotype in Southern China and Southeast
Asian countries. Synergetic contributions of viral infec-
tions, genetic alterations, and environmental factors
drive the aberrant activity of a variety of genes, which
stimulate the initiation and development of NPC. In pre-
vious investigation, we have reported that overexpressed
CDK4 was considered an unfavorable factor associated
with NPC progression and poor prognosis. Knocking
down CDK4 induced the upregulation of let-7c and the
latter further reduced cell cycle progression and cell
growth by modulating p16/CDK4/E2F1 signaling in
NPC. This demonstrated the significance of miRNA
regulation of CDK4 in NPC pathogenesis [6]. In this
study, we further study the molecular basis of CDK4
modulating miRNAs in inducing cell cycle transition,
cell proliferation, and the effect on DDP in NPC.
Methods
Sample collection and cell culture
Two NPC cell lines 5–8 F and HONE1 as well as
shCDK4-2 and shCDK4-3 [6] were obtained from
Cancer Research Institute of Southern Medical University
and maintained in RPMI 1640 medium supplemented
with 10 % newborn calf serum (NBCS) (PAA Laboratories,
Inc, Pasching, Austria) in a humidified chamber with 5 %
CO2 at 37 °C. All 63 fresh NPC and 15 NP samples (13
cases for chronic nasopharyngitis tissuses and 2 cases for
normal nasopharyngeal tissues) were obtained from an
otorhinolaryngologist using nasal endoscope. Subse-
quently, all samples were immediately stored in liquid ni-
trogen. Clinical processes were approved by the Ethics
Committees of People’s Hospital of Zhongshan City and
patients gave informed written consent.
miRNA array for shCDK4
In-house two-channel oligo-arrays (CCDTM-miRNA850-
V4px) from NIH including 713 human, mammalian, and
viral mature antisense miRs plus two internal controls
with seven serial dilutions were endowed by Professor
Wang E and Marincola FM. Six to seven microgram total
RNA samples isolated respectively from shCDK4 and its
control 5-8F cells were labeled by Cy5-dCTP and Cy3-
dCTP, respectively, in a reverse transcription reaction.
The balanced mixture of Cy5- and Cy3-labeled targets
was co-hybridized against miRNAs chip. The experiments
were repeated four times and scanned images were con-
verted to digital data by GenePixpro V6.0 (Molecular
Devices Corporation, Sunnyvale, CA, USA). Finally, the
data were analyzed using BRB ArrayToolsV3.7.2 software
(National Cancer Institute, Bethesda, MD, USA).
RNA isolation and qRT-PCR
RNA was extracted from NPC cell lines, NPC tissues
and normal nasopharynx tissues using Trizol (Takara,
Shiga, Japan). For miR-15a qRT-PCR expression analysis,
mature miRNAs were reverse-transcribed, and real-time
PCR was performed using All-in-One™ miRNA qRT-
PCR Detection Kit following the manufacturer’s protocol.
(GeneCopoeia™, Cat.No: AOMD-Q020). All data were
normalized to U6 expression. For CDK4 qRT-PCR, RNA
was transcribed into cDNA and amplified with specific
sense/antisense primer [7]. The assays were performed in
accordance with manufacturer’s instructions (Takara,
Shiga, Japan). The PCR reaction for each gene was re-
peated three times. miRNA and mRNA expression was
normalized to U6 and ARF5, respectively using the 2-
ΔΔCt method as previously described [6]. Expression
values (2-ΔΔCt) of CDK4 or miR-15a in NPC tissues
greater than or equal to the mean expression value of NP
tissues were considered high expression. Conversely, ex-
pression values of CDK4 or miR-15a in NPC tissues less
than NP tissues were regarded as low expression.
Western blot analysis
Western blot was carried out according to previous
descriptions [17, 18] with rabbit polyclonal CDK4,
GAPDH, E2F1 antibody (1:400; Santa Cruz Biotechnology,
Santa Cruz, USA); C-Myc antibody (Cell signaling tech-
nology, Danvers, USA), and CCND1 antibody (1:500;
Epitomics, Burlingame, USA). An HRP-conjugated anti-
rabbit IgG antibody was used as the secondary antibody
Liu et al. BMC Cancer  (2016) 16:238 Page 2 of 12
(Zhongshan, Beijing, China). Signals were detected using
enhanced chemiluminescence reagents (Pierce, Rockford,
IL) and Bio-RAD ChemiDox XRS.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was carried out
according to previous descriptions [12, 13]. DNA–pro-
tein complexes were immunoprecipitated from 5-8F and
HONE1 cells with the transfection of c-Myc cDNA by
using the Chromatin Immunoprecipitation Kit (Millipore,
Billerica, MA, USA), according to the manufacturer’s proto-
col with 1 mg polyclonal c-Myc antibody or 1 mg normal
mouse IgG (Millipore). Precipitated DNA was subjected to
PCR analysis using specific primers (Forward:5′
AAATGCCTGTGGGCTGGTAGCT3′; Reverse: 5′GCCG
CGGAGGTGAAGTGAACT3′) to amplify across the
DLEU2/miR-15a promoter region [19]. Finally, DNA was
analyzed by 1 % agarose gel electrophoresis.
Luciferase activity assay
The plasmids including pGL3-control and pGL3-pro-
moter used for luciferase reporter gene expression analysis
were bought from Promega Ltd. pGL3-Wild DLEU2 1A
promote vector(pGL3-W) containing c-Myc binding site
(CACGTG) was constructed by RT-PCR using specific
primers(Forward:5′AAGAGCTC(Sac I)AAGCCGGCAGG
GCGGTTTT3′;Reverse: 5′AACTCGAG(XhoI)TACCGAC
TGCGCCAGCCTTG3′). Meanwhile, pGL3-Mutant vec-
tor with a mutated c-Myc binding site (CGCATT) in the
DLEU2 regulatory region was also constructed. 5-8F cells
with exogenous c-Myc expression were plated in 24-well
plates at a density of 1 × 104 cells/well. After 24 h, pGL3-C
pGL3-W or pGL3-M were respectively transfected with
pcDNA3.1/c-Myc or its control vector were introduced
into 5-8F cells using Lipofectamine 2000. After 48 h, fire-
fly luciferase activity was measured using the dual lucifer-
ase reporter assay system according to the manufacturer’s
protocol.
Transient transfection with miR-15a mimics and its
inhibitor
miR-15a mimic and its inhibitor were designed and syn-
thesized by Guangzhou RiboBio (RiboBio Inc, China).
Twenty-four hours prior to transfection, NPC cells were
plated onto a 6-well plate or a 96-well plate (Nest, Bio-
tech, China) at 30–50 % confluence. They were then
transfected into cells using TurboFectTM siRNA Trans-
fection Reagent (Fermentas, Vilnius, Lithuania) accord-
ing to the manufacturer’s protocol. Cells were collected
after 48–72 h for further experiments.
miRNA target validation
CCND1 were predicted to be directly regulated targets
of miR-15a miRwalk softwares (University of Heidelberg,
Mannheim, Germany). A 289 fragment of CCND1 3′
UTR amplified by PCR primers (Sense:5′-AACTCG
AGCCATTTTCTTATTGCGCTGC-3′; Antisense:5′-AA
GCGGCCGCGGCTAAGTGAAGCATGAGGT-3′) was
cloned into psiCHECK-2 vectors (named wt) with XhoI
and NotI restriction enzyme sites. Site-directed muta-
genesis of the miR-15a binding site in CCND1 3′UTR
was performed using GeneTailor Site-Directed Mutagen-
esis System (Invitrogen; named mt). For reporter assays,
wt or mt vector and the control vector psiCHECK-2 vec-
tor were cotransfected into SUNE1 cells with miR-15a
mimics or inhibitor. Luciferase activity was measured at
48 h after transfection using the Dual-Luciferase Re-
porter Assay System (Promega Corporation, Madison,
WI, USA).
Cell proliferation analysis
Cell proliferation was analyzed using MTT assay as de-
scribed previously [17, 18]. For miR-15a inhibitor and
mimics, the cells were incubated for 1, 2, or 3 days.
Cell cycle assay
To evaluate cell cycle distribution, cells were fixed in
70 % ice-cold ethanol for 48 h at 4 °C, and stained by in-
cubating cells with PBS containing 10 μg/mL propidium
iodide and 0.5 mg/mL RNase A for 15 min at 37 °C, and
analyzed for the DNA content of labeled cells by FACS
Caliber Cytometry (BD Bioscience, USA). Each experi-
ment was done in triplicate.
Establishment of NPC cell line with stable expression of
miR-15a
Lentivirus (GV209) particles carrying hsa-pri-miR-15a
precursor and its control were prepared. Lentiviral
transduction of 5–8 F and HONE1 cells was carried out
according to the manufactures’ protocol(Genechem
Company, Shanghai, China). The resulting cells were
seeded onto 96-well plates and cultured for 3 weeks to
produce a stable miR-15a-overexpressing 5-8F and
HONE1 cells and their respectively control cells. High
expression of miR-15a was validated by qRT-PCR.
In vivo tumorigenesis in nude mice
A total of 1 × 106 logarithmically growing miR-15a-
overexpressing 5-8F and HONE1 cells and their control
cells in 0.1 ml RPMI 1640 medium were respectively
subcutaneously injected into the left or right flank of 4–
6-week-old male BALB/c nu/nu mice (N = 5). Mice were
maintained in a barrier facility on HEPA-filtered racks
and fed with an autoclaved laboratory rodent diet. All
animal studies were conducted in accordance with the
principles and procedures outlined in Southern Medical
University Guide for the Care and Use of Animals. After
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25 days the mice were killed, and tumor tissues were ex-
cised and weighted.
MTT cytotoxicity assay
NPC Cells (5-8F and HONE1) with miR-15a overexpres-
sion or their control cells were respectively seeded in
96-well plates in 100 μl DMEM medium supplemented
with 10 % FBS at 5 × 103 cells/well. Once the cells at-
tached, they were respectively treated with DDP in 2.5,
5, 10, 20, 30, 40 or 50 μM (0.5 mg/ml) and incubated at
37 °C in 5 % CO2 for 48 h. Subsequently, 10 μl of MTT
(5 mg/ml) (Sigma, StLouis, MO, USA) was added to
each well, and the plates were incubated at 37 °C for
4 h. Further, the supernatants were removed and
100 μl of DMSO (Sigma) was added to each well.
The absorbance value (OD) of each well was measured at
490 nm and half maximal inhibitory concentration (IC50)
was calculated. Experiments were performed three times.
Statistical analysis
All data were analyzed for statistical significance using
SPSS 19.0 software. The Student’s test was applied to
examine the differences of mRNA expressions of CDK4
and miR-15a between normal epithelium and cancer tis-
sues of nasopharynx. The relationship between CDK4
and miR-15a expression levels was analyzed using pear-
son test. Two-tailed Student’s t-test was used for com-
parisons of two independent groups. One-way ANOVA
was used to determine the differences between groups
for all in vitro analyses. A P value of less than 0.05 was
considered statistically significant.
Results
Stably downregulated CDK4 expression induced the
expression of miR-15a in vitro in NPC
In a previous study, we demonstrated that suppressing
CDK4 expression using lentiviral-mediated shRNA inhib-
ited NPC cell proliferation and G1 to S cell cycle
transition by inducing let-7c. To further investigate the ef-
fect of CDK4 on miRNAs in NPC, we used miRNA chip
to compare the differential miRNA expression between
shCDK4-2 and shCDK4-3 and mock cells [6]. We ob-
served that knocking down CDK4 significantly stimulated
the expression of miR-15a and let-7 family members in-
cluding let-7c (Fig. 1a). Further, we validated the upregu-
lated expression of miR-15a in CDK4-suppressed 5-8F
NPC cells by real-time qPCR (Fig. 1b).
Transiently knocking down CDK4 also elevated the
expression of miR-15a
To confirm that CDK4 knockdown elevated miR-15a ex-
pression in NPC, we used siRNA-CDK4 to transfect
NPC 5-8F and HONE1 cells. We observed that siCDK4-
2 provided the greatest suppression of CDK4 mRNA
(Fig. 2a) among three siCDK4 fragments tested in NPC
5-8F and HONE1 cells. Further, we validated that
siCDK4-2 significantly downregulated CDK4 protein
levels in NPC 5-8F and HONE1 cells (Fig. 2b). Finally,
we found that transiently knocking down CDK4 by
siRNA also stimulated the expression of miR-15a
(Fig. 2c).
Inhibition of CDK4 induced miR-15a expression by sup-
pressing c-Myc expression
In a previous report, we found that inhibition of CDK4
decreased the expression of CCND1,CDK6, and E2F1
[6]. Here, we observed that stably knocking down CDK4
reduced the expression of c-Myc in NPC 5-8F cells
(Fig. 3a). Further, we observed that suppressing expres-
sion of c-Myc (Fig. 3b) markedly increased the expres-
sion of miR-15a in NPC 5-8F and HONE1 cells
(Fig. 3c).
c-Myc directly binds to the promoter of miR-15a (DLEU2)
Atrributing to the fact that the miR-15a promoter con-
tains a binding site for c-Myc, we speculated that c-Myc
Fig. 1 Stable suppression of CDK4 elevated the expression of miR-15a in NPC. a. The expression of miR-15a and let-7 family members was induced
after stable knockdown of CDK4 NPC cells based on a micro-RNA array assay. b. miR-15a expression was significantly increased in NPC cells with stably
knocking down CDK4 expression by qPCR assay. (*P < 0.05)
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Fig. 2 Transiently inhibited CDK4 by siRNA stimulated the expression of miR-15a. a. The interference efficiency of siCDK4s in mRNA level was
examined by qPCR in NPC cells. b. Western blot was used to validate the interference efficiency of siCDK4-2 on protein levels in NPC cells. c.
Transiently inhibited CDK4 stimulated the expression of miR-15a by qPCR. (*P < 0.05)
Fig. 3 Knocking down CDK4 induced miR-15a expression by suppressing c-Myc expression. a. Stable suppression of CDK4 reduced the expression
of c-Myc in NPC cells. b. si-Myc inhibited the expression of c-Myc in NPC cells. c. Transiently inhibited c-Myc by siRNA stimulated the expression
of miR-15a. (*P < 0.05)
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negatively modulate miR-15a expression. To test this, c-
Myc was transfected into NPC 5-8F and HONE1 cells.
The results indicated that c-Myc was highly expressed in
NPC cells compared to mock cells (Fig. 4a). Further,
overexpressed c-Myc significantly reduced the expres-
sion of miR-15a in NPC 5-8F and HONE1 cells. Finally,
chromatin immunoprecipitation combined with PCR
analysis (Fig. 4c) and luciferase reporter assay (Fig. 4d)
were used to confirm that c-Myc could directly bind its
promoter in NPC.
miR-15a suppresses cell proliferation and cell cycle
progression in vitro and in vivo in NPC
To investigate the effect of miR-15a on NPC, we intro-
duced miR-15a mimics into NPC 5–8 F and HONE1
cells. Compared to negative controls, we found that
miR-15a mimics inhibited cell growth and cell cycle pro-
gression from G1 to S and G2 in vitro in NPC cells by
MTT (Fig. 5a, b) and cytometry assays (Fig. 5c, d). Fur-
ther, we established stable overexpression of miR-15a in
NPC 5-8F and HONE1 cells using lentiviral infection
Fig. 4 c-Myc binds to the promoter of miR-15a in NPC cells. a. c-Myc cDNA was transfected to 5–8 F and HONE1 NPC cells and its protein expression
was examined by western blot. b. Overexpressed c-Myc reduced the expression of miR-15a in NPC cells. c. Crosslinked chromatin preparation from
mock and pcDNA3.1-C-Myc transfected 5-8F and HONE1 cells was immunoprecipitated with anti-C-Myc. The c-Myc binding sites on the
immunoprecipitated DNA was determined by PCR. Amplification of input chromatin (input) before immunoprecipitation was served as
positive controls for chromatin extraction and PCR amplification. Chromatin immunoprecipitation using normal human IgG served as a
negative control. The result indicated that overexpressed c-Myc could bind more miR-15a promoter region than that in control group in
NPC cells. d. Luciferase reporter assay indicated that c-Myc could directly bind miR-15a promoter in NPC. (*P < 0.05)
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Fig. 5 miR-15a suppressed cell cycle progression and cell growth in NPC. a and b. miR-15a mimics inhibited cell proliferation in NPC 5-8F
and HONE1 cells by MTT assay. c and d. miR-15a mimics blocked cell cycle progression from G1 to S phase in NPC 5-8F and HONE1 cells. e.
Lentivirus-mediated expression of miR-15a suppressed tumorigenesis of NPC 5-8F and HONE1 cells in vivo in nude mice. f and g. miR-15a
inhibitor partially restored cell proliferation in CDK4-suppressed NPC cells. (*P < 0.05)
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(Additional file 1: Figure S1). An in vivo tumorigenesis
study inoculating these cells into nude mice showed that
the average tumor weight was significantly decreased in
miR-15a-overexpressing xenografts compared with their
respectively controls (Fig. 5e).
miR-15a antagonizes the action of CDK4 in NPC
To investigate the effect of miR-15a on CDK4 in NPC,
we introduced miR-15a inhibitor into CDK4-suppressed
NPC cells (shCDK4-2 and 3). We observed that sup-
pression of miR-15a using inhibitor (Additional file 2:
Figure S2) partially restored the cell proliferative abil-
ity (Fig. 5f, g). Our results demonstrated that miR-15a
is a potential tumor suppressor in NPC.
miR-15a suppresses c-Myc/CCND1/CDK4/E2F1 pathway
in NPC
In a previous investigation, miR-15a was reported to dir-
ectly target CCND1, thereby suppressing tumor cell
growth [20, 21]. In this study, we found that miR-15a
mimics not only reduced CCND1 expression, but also
suppressed the expression of c-Myc, CDK4 and E2F1 in
NPC 5-8F and HONE1 cells (Fig. 6a). Our results sug-
gest a feedback loop between CDK4 and miR-15a.
miR-15a directly targeting CCND1
To further study the mechanism of miR-15a suppressing
cell proliferation, we explored its directly target gene in
NPC. Interestingly, CCND1 was predicted as the directly
target gene by bioinformatics assay. We observed that
Fig. 6 miR-15a modulated cell cycle signaling in NPC. a. miR-15a mimics decreased the expression of key cell cycle transition factors including
c-Myc, CCND1,CDK4, and E2F1. b. Luciferase reporter assay was used to determine miR-15a directly targeting the 3′UTR of CCND1. (*P < 0.05)
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Wild-type (wt) or mutant (mt) 3′UTR vector of CCND1
and miR-15a mimics or inhibitor NPC cells were cotrans-
fected with NPC SUNE1 cells. The results showed a signifi-
cant decrease of luciferase activity in wt vector transfected
with miR-15a mimics (Fig. 6b, lanes 1; P < 0.001) or an ob-
vious increase of luciferase activity by using miR-15a inhibi-
tor (Fig. 6b, lanes 3; P < 0.001) when compared with miR
control, whereas the activity of mt vector was unaffected
(Fig. 6b, lanes 5 and 6) by using miR-15a mimics or inhibi-
tor. Taken together, these results strongly supported that
CCND1 was the direct targets of miR-15a in NPC cells.
Silencing of CDK4 and ovexpressed miR-15a respectively
enhance DDP chemosensitivity to NPC cells in vitro and
in vivo
The NPC cell line stably downregulating CDK4 exhib-
ited significantly increased sensitivity to DDP. The re-
sults indicated that the IC50 of DDP was 28.43 μM in
the parental NPC 5–8 F cells, whereas reduced to
16.12 μM in CDK4 silencing NPC 5–8 F cells (Fig. 7a).
Further, we evaluated the effectiveness of DDP in miR-
15a-overexpressed NPC 5–8 F cells. The results showed
that IC50 value was significantly reduced in miR-15a-
overexpressed NPC cells (14.40 μM) compared with the
control cells treated with DDP (31.43 μM).
CDK4 mRNA expression is negatively weak correlated
with expression of miR-15a
Due to the existence of feedback regulation loop be-
tween CDK4 and miR-15a, we speculated that CDK4
expression is negatively correlated with expression of
miR-15a. To confirm this hypothesis, we examined the
expression of CDK4 mRNA and miR-15a in NPC and
NP tissues. There was an increased tendency of CDK4
mRNA in NPC tissues compared to NP tissues (P =
0.0920) (Fig. 8a). On the contrary, miR-15a was down-
regulated expression in NPC tissues compared to NP
tissues (p = 0.0323) (Fig. 8b). Further, a significantly in-
verse weak correlation was observed between CDK4
mRNA and miR-15a expression in NPC tissues (Fig. 8c).
Discussion
CDK4 is a member of the cyclin-dependent kinase fam-
ily and a key factor for cell cycle signaling during transi-
tion from G1 to S phase. CDK4overexpression has been
observed in many tumor types, including NPC. In previ-
ous report, we had observed that knocking down CDK4
induced let-7c through cell cycle signaling, and let-7c in
turn suppressed cell proliferation and cell cycle progres-
sion by modulating p15/p16/CDK4/E2F1 [6]. This study
suggested that CDK4 promoted NPC pathogenesis by
modulating miRNAs. However, CDK4-mediated miR-
NAomics linking to the initiation and development of
NPC had not been investigated.
In this study, we used miRNA array to observe the
differential expression of miRNA in CDK4-suppressed
NPC cells. Interestingly, let-7 family members including
let-7c reported by us [6] were shown to be elevated ex-
pression after knocking down CDK4 NPC cells. Tumor
suppressor miR-15a was also observed to be upregulated
in CDK4-suppressed NPC cells. Further, we confirmed
the increased expression of miR-15a after stably or tran-
siently knocking down CDK4 NPC cells by qPCR, which
demonstrated that CDK4 negatively modulates the miR-
15a expression in NPC.
In previous study, we demonstrated that CDK4 in-
duced the expression of transcription factor E2F1 by
modulating CCND1, CDK6, p21, and pRB in NPC cells
[6]. Because E2F1 directly binds to the promoter of c-
Myc and stimulates the expression of c-Myc [22], we
speculated that CDK4 positively regulates c-Myc expression
in NPC. Consistent with this expectation, we observed
downregulated expression of c-Myc after knockdown of
CDK4 in NPC cells.
c-Myc is an key oncogenic transcription factor pro-
moting cellular proliferation and cancer stemness in
NPC [23, 24]. Furthermore, our recent studies indicated
that c-Myc directly modulated the expression of miR-
184 and miR-18b participating in the pathogenesis of
NPC [17, 18]. In previous study, c-Myc had been re-
ported to directly bind to the promoter of DLEU2 gene
Fig. 7 Knocking down CDK4 or increased miR-15a induced the sensitivity of NPC cells to DDP. a. Knocking down CDK4 elevated the sensitivity of
NPC cells to DDP. b. Overexpressed miR-15a stimulated the increased sensitivity of NPC cells to DDP
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which encompasses the tumor suppressor miR-15a. This
binding in turn decreases expression of both DLEU2
and miR-15a [25]. We speculated that upregulation of
miR-15a mediated by CDK4 suppression was at least in
part modulated by c-Myc in NPC. We used siRNA to
knock down c-Myc and observed that the expression of
miR-15a was significantly increased in NPC cells. Fur-
ther, we utilized chromatin immunoprecipitation com-
bined with qPCR assays and found that c-Myc directly
bind to the miR-15a promoter in NPC. Furthermore, we
observed the significant reduction of luciferase activity
in c-Myc-binded miR-15a promoter. Our investigation
demonstrated that c-Myc directly suppressed the expres-
sion of miR-15a in NPC cells.
miR-15a has been identified as a tumor suppressor in
some tumor types [20, 21, 26–32]. However, its role in
NPC has not been yet reported. In this study, we found
that miR-15a inhibited cell cycle progression from G1 to
S phase and cell growth in vitro and in vivo in NPC
cells. We also observed that miR-15a inhibitor partially
restored cell growth in CDK4-suppressed NPC cells.
These results demonstrated that miR-15 functions as a
tumor suppressor and could overcome the action of
CDK4 in NPC.
In previous reports, miR-15a had been reported to dir-
ectly suppress the expression of Sox5, which induced the
blockage of cell growth, migration, and invasion in
pituitary tumors. Furthermore, miR-15a directly targets
Cripto, Bmi-1, CCNE1, RECK, VEGF, CCND1, and
BCL-2 to suppress the malignant phenotypes in various
tumors including NSCLC, pancreatic ductal adenocar-
cinoma, breast cancer, neuroblastoma, multiple mye-
loma, and osteosarcoma [20–22, 25–32]. However, the
molecular basis of miR-15a has never been reported in
NPC. In this study, miR-15a was observed to block cell
cycle transition at G1/S, which was a key factor inducing
cell growth arrest in NPC. We suspected that miR-15a
mediated the suppression of NPC cell growth based on
its modulation of cell cycle factors. We observed that
miR-15a not only directly inhibited the expression of
CCND1, one its known direct targets, but also downreg-
ulated the expression of CDK4, c-Myc, and E2F1. These
results demonstrated that miR-15a suppressed cell
growth through c-Myc/CCND1/CDK4/E2F1 signaling in
NPC. More interestingly, a positive feedback loop of
CDK4-c-Myc-miR-15a was observed, which was similar
to our previous report for CTGF-C-Jun/C-Myc-miR-18b
and CDK4-E2F1-let-7c which promotes NPC pathogen-
esis [6, 17].
Cell cycle arrest is a key factor that usually induced
the elevation of chemotherapy sensitivity in tumor [33–
35]. In this study, we observed that knocking down
CDK4 and overexpressed miR-15a significantly induced
the chemotherapy sensitivity of DDP by inhibiting cell
cycle progression, which hinted the negatively abnormal
feedback loop between CDK4 and miR-15a as an
important signal resisting chemotherapy in NPC
pathogenesis.
We have previously reported increased expression of
CDK4 in NPC [5–7]. However, the correlation between
Fig. 8 The increased expression of CDK4 mRNA was negatively weak correlated with the reduced miR-15a expression in NPC. a. CDK4 mRNA was
upregulated in NPC tissues compare to NP tissues. b. miR-15a expression was upregulated in NPC tissue compare to NP tissues. c. CDK4 mRNA
was negatively weak correlated with the expression of miR-15a in NPC
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CDK4 expression and miR-15a has not been docu-
mented. In this study, we observed elevated CDK4
mRNA and decreased expression of miR-15a in NPC
tissues compared to nasopharynx tissues. Further, we
found that CDK4 mRNA expression was negatively weak
correlated with the expression of miR-15a in NPC
tissues.
Conclusions
In summary, our study demonstrated that knocking
down CDK4 induced the activation of miR-15a by
modulating the CDK4/E2F1/c-Myc pathway. This in
turn suppressed cell proliferation and inducing chemo-
therapy sensitivity by controlling c-Myc/CCND1/CDK4/
E2F1 signaling, and suggested an abnormal automodula-
tory feedback loop of CDK4-c-Myc-miR-15a which pro-
moted NPC pathogenesis and acquired DDP resistance.
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